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Summary 
The induction of monocyte/macrophage procoagulant activity (PCA) has been implicated in 
the pathogenesis of murine hepatitis virus strain 3 (MHV-3)  infection and disease. Previously, 
we have shown that induction of PCA by MHV-3 correlated with resistance/susceptibility to 
infection in different mouse strains.  In this study, all BALB/cJ mice that were infected with 
103 plaque-forming units of MHV-3 developed severe liver disease and died within 96-120 h. 
Examination of the livers of these animals showed marked hepatic necrosis, deposition of fibrin, 
and cellular  expression  of PCA by direct immunofluorescence staining in areas of necrosis as 
well as in hepatic sinusoids. Splenic mononuclear cells recovered from these mice expressed high 
concentrations of PCA with time after infection. Infusion into mice of a high-titered monoclonal 
antibody that neutralized PCA (3D4.3) attenuated the development of hepatic necrosis and enhanced 
survival in a dose-dependent manner. All of the animals receiving 100 #g, and 44% and 22% 
of the animals that received 50 and 25 #g per day, respectively, survived for 10 d and made a 
full recovery. Administration of the antibody resulted in a dose-dependent reduction in fibrin 
deposition, PCA expression as detected by direct immunofluorescence  staining and by a functional 
assay. In animals treated with high concentrations of antibody, titers of antibody to PCA fell 
from 87  +_  15/~g/ml to 100  +_ 7 ng/ml during the active phase of the disease, consistent with 
sequestration due to binding of the immunoglobulin to cells expressing PCA. Surviving animals, 
when rechallenged with MHV-3,  had a 40%  mortality, consistent with the known rates  of 
metabolism of immunoglobulin. This further suggested that protection was by a passive mechanism. 
The results reported here demonstrate that a neutralizing antibody to PCA protects animals from 
fulminant hepatitis and death associated with MHV-3 infection, and supports the notion that 
PCA is a potent inflammatory mediator that plays a pivotal role in the pathogenesis of liver 
injury resulting from MHV-3 infection. 
M 
urine hepatitis virus strain 3 (MHV-3), 1 a member of 
the coronavirus family, is a universally fatal infection 
in fully susceptible BALB/cJ mice even when mice are in- 
fected with as little as 0.1 PFU (1). Recent investigations have 
implicated the induction of monocyte/maerophage proco- 
agulant activity (PCA), a prothrombinase, in the pathogen- 
esis of MHV-3 infection and disease (2-4).  Previously,  we 
demonstrated that MHV-3 induction of PCA correlated with 
resistance/susceptibility to infection in different mouse strains 
1 Abbreviations used in this paper: MHV-3, murine hepatitis virus strain 3; 
PCA, procoagulant activity; p.i., postinfection; SMNC,  splenic mono- 
nuclear cells. 
(2-4). Furthermore, using recombinant inbred strains of mice, 
we showed that genetic linkage between resistance/suscepti- 
bility to MHV-3 infection and induction of PCA was con- 
trolled by  two  non-H2-1inked recessive genes  (5).  After 
infection with MHV-3, disturbances of the hepatic microcir- 
culation associated with sinusoidal thrombosis occurred coin- 
cident with the rise in PCA (6, 7). Intravenous infusion of 
macrophages, induced to express high amounts of PCA by 
MHV-3, resulted in rapid (2-5 min) death from disseminated 
intravascular coagulation in both susceptible and resistant mice 
(our unpublished observations). Together, these observations 
suggest that coagulative necrosis occurring as a result of in- 
duction of PCA may be a crucial feature of MHV-3-induced 
hepatic injury. 
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induced macrophage PCA (8). The antibodies did not react 
with purified viral proteins nor did they inhibit viral replica- 
tion. One of these mAbs (3D4.3),  an IgG2ak,  strongly in- 
hibited PCA expression in a one-stage dotting assay and in- 
hibited  conversion of prothrombin  to  thrombin  (8).  This 
antibody had no reactivity with murine,  rabbit,  or human 
tissue factor. The monoclonal bound to a 70-kD protein that 
is distinct  from  murine  and  human  tissue  factor (42  kD) 
(9, 10). 
The purpose of this study was to determine whether treat- 
ment with  this  specific murine  antiprothrombinase  would 
modify the morbidity and/or mortality associated with mu- 
rine hepatitis  virus infection. 
Materials and Methods 
Virus.  The origin and growth of MHV-3 have been previously 
described (2). MHV-3, obtained from the American Type Culture 
Collection (Kockville,  MD) (ATCC-VR262), was plaque purified 
on monolayers of DBT cells. Stock virus was grown to a titer of 
2.8  x  107 PFU/ml in 17 CL1 cells. The virus was harvested by 
one cycle of freeze-thawing and clarified by centrifugation at 4,500 g 
for 1 h at 4~  Virus was then assayed on monolayers of L2 cells 
in a standard  plaque assay as previously described  (2). To induce 
MHV-3 infection, each mouse received 103 PFU of MHV-3 by in- 
traperitoneal injection. 
Mice.  BALB/cJ  mice 8-10  wk  of age,  were obtained  from 
Charles River Laboratories, (St. Constant, Quebec). Animals were 
housed in the D  class facility at the University of Toronto fed a 
diet of standard chow and water ad libitum. Mice were killed on 
days 1, 3, 5, 7, 10, and 14 after infection. Blood was obtained by 
axillary bleeding. Splenic mononuclear cells were harvested and as- 
sayed for PCA both by immunofluorescence staining and in a one- 
stage clotting assay. Livers were harvested for viral titers, histo- 
pathology, and PCA by immunofluorescence staining as described 
below.  All mice used were screened by an ELISA for exposure to 
MHV, and were found to be negative (11). 
Anti-PCA mAt~  The preparation of mAb 3D4.3 has been pre- 
viously described (8). After injection of 106 hybridoma cells into 
Pristane-primed CAF1 mice, ascites was harvested.  Animals were 
treated with ascitic fluid containing 25,  50,  or 100 #g of mAb 
daily  for  7  d  preinfection and  7  d  postinfection  (p.i.)  by  in- 
traperitoneal injection. As a standard control, 100 ~1 of ascites from 
animals  that were infected with SP2 myeloma cells was injected 
into six separate mice. All ascitic fluid whether from SP2- or 3D4.3- 
injected mice had no reactivity with MHV-3 either in the ELISA 
or plaque reduction assays (8). To ensure that the protective effect 
of ascites containing mAb  to PCA was  specific, mAb  to PCA 
(3D4.3) was isolated from hybridoma supematants by affinity chro- 
matography using goat anti-mouse IgG immobilized on Sepharose 
4B (Pharmacia,  Montreal, Quebec). Immunoblot analysis of the 
column eluate confirmed that IgG was the only Ig present. Sub- 
class analysis by ELISA, as previously described (8), confirmed that 
IgG2ak was the only subclass present. 100 #g of the purified mAb 
was injected into 10 mice for 7 d preinfection and for 7 d p.i.  as 
described above. 
Histology.  Histology was assessed by a blinded observer as pre- 
viously described (8). Briefly, li~r  were cut into 1.0  x  0.2-cm 
blocks and fixed by immersion into 10% formalin in 0.1  molar 
phosphate buffer, pH 7.4. After fixation, the tissue was dehydrated 
in graded alcohols  and xylene, then embedded in paraffin.  4-#m 
sections were cut, stained with Harris' hematoxylin for 4 min, and 
counterstained with eosin Y for 30 s. The sections were then washed 
with distilled water, dehydrated in graded alcohols and xylene, and 
mounted with Parmount. For each group five animals were used. 
To quantitate the effect of the mAb on liver histology, a digitalized 
image analysis system (HP-88; Hewlett Packard Co., Ltd., Missis- 
sauga, Ontario) with customized software was used. This consti- 
tutes a modification of a technique described previously (12). The 
areas of necrosis were encircled as well as the entire section yielding 
a percentage figure representing the proportion of diseased liver 
present in that particular section. For each animal, three random 
sections were assayed in this fashion, and the mean +_ SD was cal- 
cuhted. Hbrin deposition was assessed by the Morris-Lendrum Hcro- 
Mallory stain  as previously described (13). 
Viral Titers.  Livers that had been snap frozen at  -70~  were 
homogenized in DMEM supplemented with 2% FCS and 4 mM 
glutamine as a 10% homogenate at 4~  as previously described 
(14). Viral titers of liver homogenates were then determined on 
monolayers of L2 cells in a standard plaque assay (2,  13). 
Isolation of Splenic Mononuclear Cells (SMNC).  Spleens were har- 
vested aseptically and cells teased from splenic tissue and suspended 
in 8 ml of DMEM as previously described (15). SMNC were iso- 
lated over Ficoll-Hypaque gradients (density,  1.0749) (Pharmcia) 
by centrifugation at 1,800g for 12 rain at 22~  Cells at the inter- 
face were collected. Viability was >98% as assessed by trypan blue 
exclusion. Cells were washed three times and resuspended in DMEM 
at a concentration of 4  x  106 SMNC/ml. 
Procoagutant Activity.  Samples of frozen thawed SMNC were 
assayed for the capacity to shorten the spontaneous clotting time 
of human citrated platelet-poor plasma in a one-stage clotting assay 
as previously described (12). Equal volumes (80 #1) of the cellular 
homogenate were admixed with citrated normal human platelet- 
poor plasma,  and then 80 #1 of 25 mM CaClz was added at 37~ 
to start the reaction. The time in seconds for the appearance  of 
a fibrin gel was then recorded. To establish arbitrary units, a rabbit 
brain thromboplastin standard at 36 mg dry mass/ml (Dade Divi- 
sion, American Hospital Supply, Miami, FL) was assigned a value 
of 100,000 mU. The assay was used over the range of 1-100,000 
mU, and the results were linear with normal human plasma  sub- 
strate.  Data were converted to PCA per 10  6 splenic macrophages 
and expressed as the mean and standard  deviation from six mice 
done in triplicate.  Media and buffers were all without activity in 
this assay. 
Inhibition of Viral Replication.  mAb purified from hybridoma 
cell cultures containing 3D4.3 and ascites were assayed for their 
ability to inhibit replication of MHV-3 in a standard plaque reduc- 
tion assay as previously described (8). Briefly,  100 PFU of virus 
was admixed with dilutions of purified antibody or ascites, media 
as a negative control, or a high titered anti-MHV-3-neutralizing 
antibody as a positive  control, for 30 min at 4~  The mixture 
was then added to a monolayer of L2 cells in culture medium, over- 
layed with 2% agarose, and incubated at 37~  in a 5% CO2 en- 
vironment for an additional 48 h. The effect of antibody on viral 
replication was  assessed by reduction of viral plaques  (8). 
Immunofluorescence.  Blocks of liver tissue were snap frozen in 
liquid nitrogen. Cryostat sections  ('~4 #m thick) were fixed for 
5 rain in acetone and air dried for 2 h as previously described (14). 
Unoccupied sites were then blocked with 5% horse serum in PBS, 
pH 7.4, for 2 h. mAb 3D4.3 was conjugated with FITC (Sigma 
Chemical Co., St. Louis, MO) according to the method of Thi 
and Feltkamp (16). The fluoresceinated antibody did not react with 
normal liver or uninduced normal peritoneal macrophages.  Tissues 
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room temperature, washed three times, mounted in 90% glycerol 
in PBS, and viewed on a phase-epifluorecence microscope equipped 
with a  x40 Fluotar  objective (E. Leitz,  Inc.,  Rockleigh,  NJ). 
ELISA for Anti-PCA Antibody.  Titres of antibody to PCA were 
determined  in a standard ELISA as previously described (8). 96- 
well  enzyme immunoabsorbant  assay (EIA)  plates  (Dynatech, 
McLean, VA) were coated with 50/~l/well of MHV-3-stimulated 
PCA-positive  macrophage  membranes  or  unstimuhted  PCA- 
negative membranes (4  x  10  ~ macrophage/ml)  at 4~  overnight. 
The plates were then washed three times with PBS, pH 7.5, con- 
raining 0.05% Tween 20 (washing buffer), and the unoccupied sites 
were blocked with 200/zl of 5% Ig-free horse serum (Flow Labora- 
tories, Mississauga, Ontario) that had been dissolved in washing 
buffer for 2 h at room temperature.  50-/~l/well dilutions  of sera 
from treated animals were then added to the plates and incubated 
for 1 h at 37~  After washing three times, 50 #l/well of alkaline 
phosphatase-conjugated goat anti-mouse Ig in PBS containing 0.1% 
BSA and 0.05% Tween 20 was added for I h at 37~  After three 
washings, P-nitrophenyl  phosphate in 0.1 M 2-amino-2-methyl-1, 
3-proponediol buffer, pH 10.3 (Zymed Laboratories, San Francisco, 
CA), substrate was then added. The plates were then incubated 
at 22~  for 3 h and read at 405 nM with a plate reader (Titertek 
MCC/340; ICN/Flow, Mississauga, Ontario). Antibody levels  were 
expressed (/~g/ml) by comparison  to a standard curve. 
StatisticalAnalysis.  Statistical analysis  was carried out using anal- 
ysis of variance and the Wilcoxon ranked sum test. A p value of 
0.05% or less was considered statistically significant. 
Results 
Suwival.  Mice infected with 1,000 PFU ofMHV-3 (n  = 
16) all succumbed to the infection within 5 d (Fig.  1). This 
was consistent with previous data reported by our group as 
well as others (1, 2). In contrast, there was survival in some 
animals  that were treated with ascites containing antibody 
to PCA (Fig. 1). Animals treated with ascites containing 25 
/~g/d had a 22% survival; 44% of those treated with ascites 
containing 50 #g/d and 100%  of animals treated with 100 
/~g/d survived. All animals survived when treated with 100 
/~g  of monodonal  anti-PCA  (IgG2ak),  which  had  been 
purified from hybridoma superuatant,  confirming that  the 
beneficial effect of ascites was due to the monoclonal anti- 
PCA.  Mice immunized  with  100/~1  of ascites  from SP2- 
injected animals  and infected with MHV-3 all died within 
5 d  (data not  shown). 
Liver Histology.  MHV-3-infected mice that did not receive 
antibody developed histologic evidence of severe liver disease. 
By 24 h  p.i.,  small,  discrete loci of necrosis with  a sparse 
PMN infiltrate could be seen. At 48 h, these lesions became 
both more pronounced and more numerous (Fig. 2 A), and 
by 72-96 h, confluent liver necrosis was apparent (Fig.  2 B). 
In contrast, mice infected with MHV-3 but treated with an- 
tibody to PCA showed a marked reduction in liver disease 
in all groups (25, 50, and 100/.r  (Fig. 2 C) compared with 
nontreated and MHV-3-infected animals.  Moderate necrosis 
was seen in animals treated with 25/~g of the mAb, whereas 
only a few loci of necrosis were observed in the animals treated 
with 50 #g of antibody. In the animals treated with 100/zg 
of anti-PCA, the livers appeared near normal, although there 
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Figure 1.  The effect  of antibody to procoagulant activity (3D4.3) on 
survival of mice infected with murine hepatitis virus strain 3 (MHV-3). 
Mice were either not pretreated (0) or pretreated with 25 (V), 50 (m), 
or 100/~g (A) of mAb 3D4.3 for 7 d before infection with 10  ~ PFU of 
MHV-3. Antibody was continued in treated animals for 7 d p.i. Survival 
was then studied (n  =  9/group). 
were a few small loci of inflammatory cells with no necrosis 
(Fig.  2 D).  Morphometric image analysis  showed that  the 
proportion  of the liver that  was necrotic was significantly 
different between the MHV-3-infected, anti-PCA-treated, and 
untreated groups at 48, 72 and 96 h (Fig. 3). The histolog  7 
of livers from all survivors at 10 and 14 d postinfection ap- 
peared normal. Fibrin deposits were seen in hepatic sinusoids 
as well as in areas of necrosis of untreated and MHV-3-infected 
mice (Fig.  4). In animals treated with 25 and 50/~g of anti- 
PCA, a marked reduction in fibrin was noted. No fibrin was 
seen in the livers of infected mice treated with  100/~g of 
mAb. Treatment with anti-PCA alone resulted in no detect- 
able histological evidence of liver disease in nonirLf~ed animals. 
Viral Titers.  By 24 h p.i., large amounts of infectious virus 
were recovered from liver homogenates of MHV-3-infected 
and untreated animals,  and these persisted until the death of 
the animals (Fig.  5). In animals treated with 25 and 50/~g 
of antibody to PCA, there was no significant difference in 
viral titers from those observed in untreated mice at days 1 
and 3. Viral titers remained high at day 5, however, viral titers 
decreased by day 7 and no virus could be detected after day 
10. In animals treated with the highest dose of antibody to 
PCA (100 #g/d), viral titers were markedly reduced (p <0.05) 
and approached those seen in resistant  A/J mice (3,  5). 
Using the method of Reed and Meunch,  the MHV-3 re- 
covered from infected and antibody-treated animals  was as 
pathogenic as stock MHV-3 or virus recovered from infected 
and untreated  mice (data not  shown)  (17). 
PCA.  In untreated, but MHV-3-infected animals,  a sharp 
increase in splenic macrophage PCA was noted at 24 h p.i. 
(Fig. 6). Maximal PCA was seen at 48 h and PCA remained 
elevated until the animals' death on day 4. Animals treated 
with low concentrations of antibody to PCA (25 and 50/zg/d) 
expressed high  amounts  of PCA at early time points,  but 
by day 7, PCA levels fell and only basal levels of PCA were 
detected in SMNC by day 10. In contrast,  no expression of 
691  Li et al. Figure 2.  The effect of mAb 3D4.3 on liver histology after MHV-3 infection.  Liver sections after infection with MHV-3 demonstrated  scattered, 
small loci of inflammatory cells at 48 h (A), and widespread necrosis at 72 h (B). In contrast,  pretreatment  and continual treatment with the mAb 
3D4.3  (100/zg/d) resulted in near normal histology  at 48 h, with only an occasional focus of inflammation at 72 h  (C),  and normal histology  at 
7 d  (D) (hematoxylin  and eosin stain:  x225). 
PCA could be detected in animals treated with 100/zg of 
antibody to PCA during the course of infection  (Fig. 6). 
Immunofluorescence.  By direct immunofluorescence stain- 
ing, PCA could be detected at 24 h in livers from MHV-3- 
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Figure 3.  Morphometric  analysis of liver histology. A marked differ- 
ence in the proportion of disease to normal liver is seen at 48 h (p <0.05), 
72 h, and 96 h between untreated animals infected with MHV-3 and animals 
treated with 25,  50, or 100/~g of mAb 3D4.3  *Statistical significance 
as compared with untreated animals. 
infected and untreated mice. PCA was seen  in areas of  inflam- 
mation and necrosis, and also in hepatic sinusoids, localized 
primarily in endothelial cells and Kupffer cells, but not ex- 
pressed by hepatocytes (Fig. 7). Livers from animals treated 
with antibody to PCA had significantly less PCA expression, 
although small amounts of  PCA could be seen in macrophages 
and endothelial cells in hepatic sinusoids in animals treated 
with high-dose  antibody to PCA (100 ~tg/d), even as late 
as day 14 (Fig. 7). 
Antibody to PCA.  Sera  were collected from animals at all 
time points and analyzed in an ELISA for the presence of 
antibody to PCA as previously described (8). No antibody 
to PCA could be detected in sera  from normal control animals 
or in animals infected with MHV-3 who had not received 
antibody to PCA (data not shown). Sera from animals treated 
with ascites containing 25-100/zg of antibody to PCA con- 
tained large amounts of anti-PCA before MHV-3 infection. 
After MHV-3 infection, the concentration of circulating an- 
tibody fell, but remained at >100 ng/ml in animals treated 
with 100/~g/d.  In animals that were treated with 25 and 
50/zg of antibody, by day 7, antibody was undetectable (<1 
ng/ml) (Fig. 8). 
Antibody to PCA either in ascites or purified from super- 
natants did not neutralize MHV-3 in a standard plaque reduc- 
tion assay as previously described (8) (Table 1). 
692  Monoclonal  Antiprothrombinase Prevents Murine Hepatitis  Mortality Figure 4.  Deposition of fibrin in liver after MHV-3 infection. Large deposits of fibrin were observed in sinusoids and areas of necrosis (arrows) at 
48 h after MHV-3 infection in untreated mice (Picro-MaUory Stain: x425). 
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Figure 5.  The effect of treatment with mAb to PCA on viral replica- 
tion. High titers of virus were recovered  from untreated and MHV-3-infected 
animals at all time points (O). In contrast, in a dose-dependent fashion, 
mAb 3D4.3 at concentrations of 25 (V), 50 (m), and 100/~g (A) attenu- 
ated the titer of virus recovered  from the liver. In the animals treated with 
25 and 50 #g of 3D4.3, no difference in viral titer was seen as compared 
to untreated  mice on days 1, 3, and 5.  However, titers of virus fell by 
day 7 and were not detected on day 10. Animals treated with 100 t~g of 
3D4.3 had statistically significantly lower levels of virus in their livers at 
all time points studied as compared with MHV-3-infected and untreated 
animals. *Statistical significance, ?  <0.05. 
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To determine  whether  treated  animals that  had  survived 
the acute infection developed long-term resistance to MHV-3 
infection, mice previously infected with MHV-3 and treated 
with 100/~g of antibody (n  =  15) were infected with 1,000 
PFU of MHV-3, 21 d after their last exposure to virus. PCA 
antibody  titers  in  this  group  were  ~50%  of that  present 
during antibody therapy, consistent with known rates of dis- 
appearance of IgG. The MHV-rechallenged mice experienced 
a 50% mortality rate, suggesting that protection was by pas- 
sive immunization  of antibody,  not  an acquired,  active im- 
mune process (Fig.  9).  In addition,  no antibody to MHV-3 
was detected in these mice either before or after rechallenge 
with  virus. 
Discussion 
MHV-3 infection produces fulminant  hepatic failure and 
death in BALB/cJ mice (1, 3).  The availability of a mAb to 
PCA that neutralized acceleration of coagulation in vitro (8) 
provided us an opportunity  directly to examine the role of 
PCA in vivo in murine hepatitis virus strain 3 infection.  All 
BALB/cJ mice which were infected with  103 PFU of MHV-3 1000 
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Figure 6.  The effect of treatment with mAb 3D4.3 on MHV-3 induc- 
tion of macrophage  PCA in vivo. High amounts of PCA were seen in 
MHV-3-infected  and untreated  mice (0).  Similarly, high titers  of PCA 
were seen on days 1, 3, and 5 in animals treated with 25 (V) and 50/~g 
(m) of antibody.  By day 7, the PCA was falling and was no longer de- 
tected on days 10 and 14. Animals treated with 100/zg (A) ofmAb 3D4.3 
had  no detectable  levels of PCA in splenic mononuclear cells, p  <0.05. 
developed severe  liver disease and died within 96-120 h. Ad- 
ministration of the mAb to  PCA  attenuated the hepatic 
necrosis, fibrin deposition  and enhanced survival in a dose- 
dependent manner. All of the animals receiving 100/~g, and 
44% and 22% of the animals that received 50 and 25/~g/d, 
respectively, survived for 10 d and made a full recovery. Fur- 
thermore, the same protective effect was seen  in mice treated 
with IgG2ak purified from hybridoma culture supernatants 
(3D4.3).  The increased survival of the treated animals was 
specific for anti-PCA, since ascites from mice injected with 
SP2 cells alone, which contained no antibody to PCA, failed 
to protect mice from MHV-3 infection. Although antibody- 
treated, MHV-3-infected animals demonstrated clinical evi- 
dence of viral hepatitis early in the course of the infection, 
by 7-10 d their behavior appeared normal and liver sections 
showed little or no apparent  disease. 
Examination  of the  livers of antibody-treated  animals 
showed marked reduction in hepatic necrosis and inflamma- 
tory cells (neutrophils and mononuclear  cells), each of  which 
are prominent features of MHV-3 infection (3, 6, 7). PCA 
expression is a feature of  MHV-3 infection in this mouse strain 
(2-4), and in untreated MHV-3-infected mice, PCA was de- 
tected by immunofluorescence  staining in areas of necrosis 
as well as in hepatic sinusoids. Both macrophages and en- 
dothelial cells expressed detectable PCA, but hepatocytes did 
not. It is likely that the hepatic necrosis is secondary to isch- 
emic changes resulting from induction of PCA, leading to 
the deposition of fibrin. Administration of mAb resulted in 
a dose-dependent  reduction in the deposition  of fibrin and 
in expression of PCA as detected by immunofluorescence 
staining in the liver and by a direct functional assay  in SMNC. 
Previously, we have shown that MHV-3 infection of peri- 
toneal macrophages in vitro results in the production of  PCA, 
TNF, leukotriene B4 (18),  and IL-1 (19). Thus,  expression 
Figure 7.  Direct immunofluorescence  studies of livers from MHV-3- 
infected mice. (A) At 48 h, high amounts of PCA could be seen in areas 
of necrosis as well as in macrophages and endothelial cells  in HV-3-infected 
and untreated animals. (B) However, marked reduction in the amount of 
PCA was seen in 48 h in animals  treated with 100 #g of mAb 3D4.3, 
and (C) at 10 d, only small amounts of PCA were seen in Kupffer cells 
and in endothelial cells in sinusoids with no PCA in hepatocytes (x 500). 
of PCA by endothelial  ceils might either be due to direct 
induction by MHV-3 or due to induction by IL.1 and/or TNF, 
which have previously been shown to induce PCA in en- 
dothelial cells in vitro (20,  21). 
Treatment of mice with 100/~g of mAb to PCA not only 
increased  survival  and reduced hepatic necrosis, but also resulted 
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Figure 8.  Antibody  to PCA in serum from MHV-3-infected  mice. An- 
tibody  to PCA was determined  in a standard  ELISA  as described  in Materials 
and Methods. Large amounts of antibody to PCA were detected  before 
infection in mice treated with 100 (A), 50 (I), and 25/~g (V) of mAb 
3D4.3. By day 7 p.i., antibody  was only detected in mice treated with 
100/~g/d. In contrast, no antibody  to PCA was seen in animals infected 
with MHV-3, which were not treated with antibody  (data not shown). 
The data represent the mean _+  SD of three determinations from four 
different animals at each time point. 
in a marked reduction of viral replication. In the untreated 
mice, high titers of virus were recovered early in the course 
of infection and persisted until death. The viral titers recov- 
ered from the livers of mice treated with 100 #g of antibody 
were much lower and similar to the amounts of virus recov- 
ered from the livers of MHV-3-infected resistant A/J strain 
mice (3). 
One possible explanation for the decrease in viral replica- 
tion observed in mice treated with antibody 3D4.3 is that 
this antibody reacts with the MHV receptor recently described 
by Holmes and coworkers (22, 23). We regard this explana- 
tion as unlikely, since 3D4.3 does not show any neutraliza- 
Table  1.  Effect of 3D4.3  on  Viral Replication 
Amount of 
antibody added  No. of plaques  Percent inhibition 
/~g 
0  105  •  7  0 
25  111  +  12  0 
50  99  •  16  0 
100  122  •  14  0 
100 plaques were added to L2 cells in presence or absence of antibody 
3D4.3, and after 72 h, plaques were counted  by crystal  violet staining. 
Percent  inhibition = 100 x [(A - B)/A]; where  A = number  of plaques 
on plates where no antibody was added, and B =  number of plaques 
on plates where antibody 3D4.3 added. Polyclonal  antibody  to MHV-3 
resulted in 100% plaque reduction to a titer of 1/10,000. 
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Figure 9.  Effect  of antibody 3D4.3 on survival to MHV-3 infection. 
Animals that survived  MHV-3  infection  and that had been  previously  treated 
with 100 #g of antibody (n = 15) were infected  with 103 PFU of MHV-3 
21 d after their first exposure  to virus. Animals were then monitored  for 
survival. 
tion of viral infectivity in a plaque reduction assay, whereas 
antibody to the MHV receptor does inhibit infectivity. Fur- 
thermore, the MHV receptor has a molecular mass  of 110 
kD, considerably different than that of the PCA molecule 
(74 kD). A second possible explanation for the effect of anti- 
PCA antibody on MHV-3 growth in mice is related to the 
normal cleavage of the MHV S protein. It has been shown 
that cleavage  of S by proteases is necessary to activate the 
membrane-fusing properties of the S protein (24). This fu- 
sion property facilitates the spread of virus to uninfected cells 
by cell-cell  fusion and also increases  the specific infectivity 
of MHV when compared with virus in which S has not been 
cleaved (24). It is possible that in infected macrophages, PCA, 
a serine protease, mediates at least in part  the proteolytic 
cleavage of S into $1 and $2, and thereby activates the fusion 
properties of this molecule. Consistent with this idea is the 
observation that infection of A/J macrophages, which do not 
produce PCA in response to MHV infection, does not result 
in the appearance of syncytial giant cells (our unpublished 
observations).  Thus, antibody to PCA could inhibit the spread 
of virus to uninfected cells by decreasing the activation of 
the fusion properties of S. 
Although the mechanism by which anti-PCA treatment 
protects the susceptible animals is not clear, the use of anti- 
body to PCA neutralizes PCA,  thereby preventing activa- 
tion of the coagulation system and inhibiting fibrin forma- 
tion. The antibody could also result in complement-mediated 
destruction of MHV-3-infected cells that express membrane- 
bound PCA or promote macrophage activation with restric- 
tion of viral growth. In animals treated with 100 #g of anti- 
body for 7 d before infection and 10 d p.i., concentrations 
of antibody to PCA in sera fell from 87/~g/ml before MHV-3 
infection to 100 ng/ml during the active phase of disease (day 
5), consistent with sequestration perhaps due to binding of 
the Ig to cells expressing PCA. Furthermore, in these mice, 
levels of PCA in SMNC remained at basal levels. In animals 
695  Li et al. treated with lower amounts of antibody (50 or 25 #g/d) to 
PCA, hepatic necrosis and survival were only partially  at- 
tenuated, and antibody was not detected (<1 ng/ml) after 
day 7 p.i. Together, the data strongly support the notion that 
anti-PCA antibody neutralizes PCA in vivo during the in- 
fection and that this may be the basis for its protective effect. 
In a previous report we have demonstrated that dimethyl 
prostaglandin  E2 inhibited procoagulant  activity and pre- 
vented fulminant viral hepatitis, yet all animals still succumbed 
to the infection (13). In PGE-treated mice, viral replication 
proceeded at a rate similar to that in untreated animals. Re- 
cently, we have demonstrated that although PGE2 inhibited 
functional PCA, antigenic expression of PCA was not al- 
tered as determined by Western immunoblotting (25). We 
have proposed that PCA may exert its effect through activa- 
tion of the coagulation system with microvascular and mac- 
rovascular thrombosis (6, 7), but the present results, in con- 
cert with the inhibition studies of PCA by PGE2, suggest 
that PCA has other sites of action as well. The protective 
effects  of the mAb to PCA occurred even though the BALB/cJ 
mice failed to mount an antiviral humoral response. Our ob- 
servations  are consistent with a recent report by Korner et 
al. (26) and support the notion that the murine antiviral an- 
tibody response may not be required for protection from acute 
viral infection. 
Cytokines can play a potent role in the course of inflam- 
matory injuries in vivo,  and interference with their action 
can alter the course of certain inflammatory diseases (27, 28). 
Treatment of rats with recombinant antibody to TNF has 
been shown to protect animals from the hypotension, hypo- 
thermia, and mortality of  Gram-negative sepsis (29), and treat- 
ment of rabbits with an IL-1R antagonist reduced the mor- 
tality associated with endotoxin shock (30, 31). Our studies 
support the notion that induction of PCA during MHV-3 
infection in mice is an integral and potentially central step 
in the disease. A previous report by Taylor et al. (32) demon- 
strated that lethal Escherichia coli septic shock can be prevented 
by blocking tissue factor (a distinct procoagulant) with mAb, 
demonstrating the importance of cellular coagulants in the 
pathophysiology of other infectious diseases. We conclude 
that PCA is a potent inflammatory mediator that plays a piv- 
otal role in hepatic injury resulting from MHV-3 infection. 
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